Abstract: 18
The restriction factors could potentially target the viral replication proteins, the viral RNA or 53 host-coded proteins usurped by (+)RNA viruses to aid the replication process (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . 54 7 (CCAGGGATCCATGGTCAACCCCACCGTGTTC) and #5032 134 (CCAGCTCGAGTTATTCGAGTTGTCCACAGTCAGCAATGG). The obtained PCR products 135
were digested with BamHI and XhoI and were inserted between BamHI and XhoI sites in pYC-136
His or pYC-HisFlag. Plasmids pPR-N-CypA and pPR-N-H126Q (CypAmut) were prepared as 137 follows: the above PCR products were digested with BamHI and XhoI and were ligated into 138 pPR-N-Re (50) between BamHI and SalI sites. 139
The plant over-expression plasmids were constructed as described (60). Briefly, pGD-140 Roc1, pGD-Roc2, pGD-CypA and pGD-H126Q (CypA/mut) were obtained by digesting the 141 PCR products of Roc1, Roc2, CypA and CypA-H126Q with BamHI and XhoI and were inserted 142 between BamHI and SalI sites into pGD plasmid. Plasmids pGD-p19 and pGD-CNV were 143 described earlier (60) . 144
To study the effect of cyclophilin over-expression on tombusviral RNA replication, we 145 transformed yeast parental strain (BY4741) or double mutant strain ΔCpr1/ts-Ess1 (29) with 146 three plasmids: pYC-His-H126Q, pGBK-Cup-Flag-p33-Gal-DI72 (a gift from Dr. Barajas) and 147 pGAD-Cup-Flag-p92 (50). Transformed yeast were selected on SC-ULH -plates, then pregrown 148 for 12 hours in ULH -media containing 2% glucose at 29°C. After centrifugation at 2,000 rpm 149 for 3 min and washing the pellet with selective media containing 2% galactose, yeast were grown 150 24 hours in SC-ULH -media containing 2% galactose at 34°C (in case of ΔCpr1/ts-Ess1 yeast 151 strain) or 23°C (in case of BY4741 strain). Then, yeast were grown for 8 hours in SC-ULH -152 media containing 2% galactose and 50 mol CuSO 4 at 23°C. Total RNA extraction from yeast 153 cells and Northern blotting and Western blotting were done as previously described (22, 23) . (Mal-Roc1 and Mal-Roc2 ) from E. coli were carried out as described earlier (61). Purification of 167 GST-tagged CypA, H126Q, Roc1 and Roc2 was carried out using glutathione resin as described 168 (52). The eluted recombinant proteins were aliquoted for storage at -80°C. The concentrations of 169 the purified recombinant proteins were measured by Bio-Rad protein assay (62). Protein 170 fractions used for the replication assays were at least 95% pure, as determined by SDS-PAGE. 171 172 Cyclophilin proteins purification from yeast. Yeast strain BY4741, transformed with 173 plasmid pYC-His-Flag-CypA or yeast strain expressing GST-CPR1 (a generous gift from Dr. 174 Brenda Andrews) (63) were streaked on SC-U -plates, and then were grown for 24 hours in 50 ml 175 SC-U -media containing 2% galactose at 29°C. After dilution to 250 ml in SC-U -media 176 containing 2% galactose, yeasts were grown for 18 hours at 29°C. 400 µg of pelleted yeast were 177 9 taken for affinity-purification using anti-FLAG M2 agarose in the case of HisFlag -CypA or 178 GST-binding resin n the case of GST-CPR1 as described (22, 46, 52) . 179
180
In vitro pull-down assay. MBP-binding columns were used to bind the MBP-p33, MBP-181 p33 derivatives or MBP-p92 (61). The sonicated extracts from E. coli containing the MBP-182 tagged viral proteins were added to the columns and incubated for 20 min at 4°C with mixing. 183
After binding, the affinity columns were washed three times with cold column buffer prior to 184 loading of purified GST (negative control), GST-tagged CypA, or GST-H126Q (100 g or 200 185 g) followed by incubation for 30 min at 4°C with mixing. The columns were washed three 186 times with cold column buffer, followed by elution of the bound protein complexes with MBP-187 elution buffer (column buffer containing 0.18% maltose). The presence of GST-tagged proteins 188 in the eluate was analyzed by SDS-PAGE, followed by Coomassie blue staining or Western 189 blotting with an anti-GST antibody. A fraction of MBP-p33 and MBP-p92 proteins isolated with 190 GST-tagged proteins were stored at -80°C and further used in CFE-based TBSV replication 191 assays. 192
193
RNA probes used for RNA:protein interactions. In vitro T7 transcription reaction was 194 used as described (61) to generate 32 P-labeled or unlabeled full-length DI-72 (+) and (-) RNAs. 195 Purification of transcripts for the CFE-based TBSV replication assays was done as described 196 earlier (61). A UV spectrophotometer (Beckman) was used for the quantification of RNA 197
transcripts. 198
Gel mobility-shift assay (EMSA). EMSA experiments were performed as described 200 previously (35) with minor modifications. Briefly, the binding assay was done in the presence of 201 20 mM HEPES (pH 7.4), 50 mM NaCl, 10 mM MgCl 2 , 1 mM DTT, 1 mM EDTA 5% glycerol, 202 6 U of RNasin and 0.1 g tRNA in a 10 l reaction volume. 0.1 pmol of 32 P-labeled RNA probes 203 was used together with 0.4 g or 0.8 g of recombinant proteins. The effect of CypA on binding 204 of p33C to the 32 P-labeled RNA (~0.1 pmol) was tested using 0.02 g to 0.6 g of recombinant 205
GST-CypA, or GST-H126Q and 0.02 g of p33C. Mixtures were incubated at room temperature 206 for 15 min and loaded on 5% nondenaturing polyacrylamide gel as described previously (35) . Cup-Flag-p33-Gal-DI72 and pGAD-Cup-Flag-p92 were used for FLAG-affinity-purification of 225 the membrane-bound tombusvirus replicase (Flag-p33 and Flag-p92) using anti-FLAG M2 226 agarose as published previously (33). Flag-p33 was detected with anti-Flag antibody (1/10,000 227 dilution) and AP-conjugated anti-mouse antibody (1/10,000). His 6 -CypA or His 6 -H126Q 228 proteins were detected with anti-His 6 antibody from mouse (Amersham; 1/10,000 dilution) and 229 AP-conjugated anti-mouse (1/10,000) followed by . 230
231
Northwestern assay. Northwestern was done as described (61) function, we used a purified recombinant CypA with a detrimental mutation (mutant H 126 Q) (Fig.  293 1C-D) (59). Mutant H 126 Q was as effective as the wt CypA in inhibition of TBSV replication in 294 the CFE assay (Fig. 1B, lanes 9-10 versus 7-8) . Mutant H 126 Q was also able to reduce the 295 production of dsRNA and ssRNA by up to 5-fold in vitro (Fig. 1E , lanes 9-10 versus 7-8). Based 296 on these data, we suggest that mutant H 126 Q is as potent inhibitor as the wt CypA, indicating that 297 the PPIase activity is not needed for the inhibitory effect of CypA on TBSV replication in vitro. 298
299
CypA inhibits VRC assembly in vitro. Since the recombinant CypA was a potent 300 inhibitor of TBSV replication in vitro, we used a two-step replication assay based on yeast CFE 301 (43) to determine what steps of TBSV replication could be inhibited by CypA. In this assay, the 302 first step includes VRC assembly on the endogenous membranes present in the CFE. The assay 303 also contains the viral (+)repRNA, the recombinant p33 and p92 replication proteins obtained 304 from E. coli and rATP/rGTP ( Fig. 2A, step 1 ). Under these conditions, the viral replication 305 proteins recruit the (+)repRNA to the membrane and the VRC becomes partially RNase and 306 protease insensitive. The pre-assembled VRC, however, cannot initiate minus-strand synthesis 307 yet, due to the absence of rCTP/rUTP (43). Then, during the second step, centrifugation and 308 washing the membranes will remove all the proteins and molecules not bound to the membrane. 309
Addition of rATP/rCTP/rGTP/ 32 P-labeled rUTP to the membrane fraction of the CFE then 310 initiates asymmetrical (-) and (+)-strand RNA synthesis in vitro. 311
We found that addition of purified recombinant CypA during the first step ( Fig. 2A)  312 inhibited TBSV replication up to ~90% (Fig. 2B , lanes 8-9 versus 5-7), similar to the strong 313 on September 14, 2016 by guest http://jvi.asm.org/ Downloaded from 15 inhibitory effect of CypA during standard CFE replication assay (Fig. 1A-B ). This suggests that 314
CypA strongly inhibits VRC assembly in vitro. Interestingly, the PPIase inactive mutant H 126 Q 315 was again as potent an inhibitor as the wt CypA (Fig. 2B, lanes 10-11) , confirming that the 316 PPIase function is not required to block TBSV replication. Importantly, CypA was as strong an 317 inhibitor as Cpr7p (lanes 12-13), demonstrating that a single-domain cyclophilin can be as 318 effective inhibitor of TBSV replication as the TPR-domain containing Cpr7p. Roc1 and Roc2 319 also inhibited TBSV replication when added during the 1 st step of the CFE assay (Fig. 2B , lanes 320 1-4 versus 5-7), further demonstrating that these Arabidopsis cyclophilins have similar activity to 321
CypA to inhibit TBSV replication in vitro. 322
In contrast, addition of CypA, its mutant or Roc1 and Roc2 exclusively during the second 323 step of the CFE assay inhibited TBSV RNA replication only by 10-to-20% (Fig. 2C ). These data 324 are similar to that obtained with Cpr7p (Fig. 2C , lane 7) (52). We suggest that the lack of 325 inhibition of viral RNA synthesis by cyclophilins after the VRC assembly step (i.e., during the 326 second step of the CFE assay, Fig. 2A ) is due to the inaccessibility of the membrane-bound pre-327 assembled replicase by proteins (possibly due to physical hindrance and/or the membranous 328 structure of the VRC). 329
To further test the effect of CypA on VRC assembly, we performed a second CFE assay, 330 in which the tombusvirus p33 and p92 replication proteins were expressed in yeast prior to CFE 331 preparation. This approach allows the membrane insertion of p33 and p92 and the formation of 332 pre-VRCs in intact yeast cells in the absence of the viral RNA (38). Then, CFE is prepared and 333 programmed with (+)repRNA in the presence or absence of purified recombinant CypA. We 334 found that CypA or H 126 Q were able to efficiently inhibit TBSV ssRNA and dsRNA production 335 in this assay (Fig. 3A, lanes 5 and 7) . This suggests that CypA inhibits TBSV replication not 336 We also tested if the pre-assembled and active VRCs from yeast could be inhibited by 341 addition of CypA in the CFE assay (Fig. 3B) . These membrane-bound VRCs already contain the 342 endogenous viral RNA (38). The added CypA or H 126 Q were unable to inhibit TBSV replication 343 in this assay (Fig. 3B, lanes 3 and 4) . This confirmed that the pre-assembled and active VRCs are 344 not accessible to CypA. 345
346
CypA is associated with the viral replicase and binds to the RNA-binding region of 347 the viral replication proteins. The inhibitory effect of a cellular protein on TBSV replication 348 could be due to the effect of the given host protein on cellular factors co-opted for viral 349 replication, on viral factors or due to indirect effects on host metabolism. To identify the target of 350
CypA, first, we tested if CypA is present in the tombusviral VRCs. We isolated the membrane 351 fraction from yeast containing the tombusviral VRCs, followed by affinity purification of the p33 352 replication protein, the most abundant component of the VRC (33). We found that CypA was co-353 purified with the tombusvirus replicase from yeast ( Fig. 4A-B, lane 1 versus 2) . The H 126 Q 354 mutant was also co-purified (Fig. 4A, lane 3) , suggesting that the PPIase activity is not needed 355 for its recruitment. 356
To test if CypA interacts with p33 replication protein, we performed a MYTH (split-357 ubiquitin) membrane-based yeast two-hybrid assay. As expected based on prior Cpr1p studies 358 (29), CypA interacted with p33 (Fig. 5A) . The interaction of Roc1 and Roc2 with p33 was also 359 on September 14, 2016 by guest http://jvi.asm.org/ Downloaded from 17 detected in the same assay (Fig. 5A) . Interestingly, the interaction between H 126 Q and p33 was 360 noticeably weaker than the binding of p33 to the wt CypA (Fig. 5A) . This was also confirmed in 361 a pull down experiment that indicated ~3 times less efficient binding between H 126 Q and either 362 p33 or p92 than wt CypA (Fig. 5B , lanes 3 and 6 versus 2 and 5; see also 5C, lanes 5 and 8 363 versus 4 and 7). Based on these data, we propose that the sequence or the activity of the PPIase 364 domain in CypA is critical for efficient binding to p33 and the over-lapping p92 replication 365
proteins. 366
To study if the interaction between CypA and p33/p92 is relevant for the inhibitory effect 367 on TBSV replication, we affinity-purified p33/p92:CypA complex, followed by addition of the 368 complex as a sole source of p33 and p92 to the CFE-based TBSV replication assay (Fig. 5D) . 369
Interestingly, the p33/p92:CypA complex supported TBSV replication poorly (at 8% level), 370
suggesting that binding of CypA to the replication proteins blocks their replication function. In 371 contrast, H 126 Q mutant was less effective in this function than the wt CypA (Fig. 5D, lanes 3-4  372 versus 5). This is likely due to the reduced binding of H 126 Q mutant to p33/p92 complex in vitro. 373
To map the CypA binding site in the overlapping TBSV replication proteins, we have 374 used pull-down experiments with immobilized MBP-p33 and its truncation derivatives (Fig. 6A)  375 and E. coli lysate containing GST-tagged CypA. These experiments revealed that CypA binds to 376 the arginine-proline-rich (RPR) motif in p33 (Fig. 6A-B) . Indeed, deletion of the RPR motif 377 inhibited p33 binding to CypA (p33CΔRPR, Fig. 6B, lane 2) . The RPR-motif represents the 378 RNA-binding site in p33 and p92 replication proteins required for specific viral (+)RNA 379 recruitment and replicase assembly (35, 61, 64) . 380 18 CypA binds to the viral RNA and inhibits the recruitment of the viral RNA for 382 replication. The observation that H 126 Q mutant inhibits TBSV replication as efficiently as the wt 383
CypA in the CFE assay (Fig. 1 ), yet H 126 Q mutant, unlike the wt CypA, binds inefficiently to the 384 viral replication proteins (Fig. 5, 6B ) suggests that there must be additional target for CypA and 385 H 126 Q that affects the efficiency of TBSV inhibition. Therefore, we tested the binding activity of 386
CypA to the viral RNA using purified recombinant protein (Fig. 7A) . The EMSA assay revealed 387 that both CypA and H 126 Q mutant bound to the viral (+)RNA efficiently, and even more to (-388 )RNA (Fig. 7A-C) . Similarly, we also observed that the Arabidopsis Roc1 can bind to the viral 389 RNA (Fig. 7B , lane 5), albeit less efficiently than CypA. Viral (-)RNA binding by the 390
Arabidopsis Roc2 was undetectable (Fig. 7B, lane 4) . In contrast, Cpr7p Cyp40-like cyclophilin 391 did not bind to the viral RNA under the same conditions (Fig. 7B, lanes 11-12) . We confirmed 392 the viral RNA binding ability of the E. coli-expressed CypA and H 126 Q mutant (Fig. 7D, lanes 2-393 3) and the yeast-expressed CypA (Fig. 7D, lane 1) using Northwestern assay. 394 Viral RNA binding by CypA suggests that CypA might affect various functions of the 395 viral RNA in cells. Therefore, we tested if CypA could affect the selective binding of p33 to the 396 p33RE (p33 recognition element), which is required for replication, using an EMSA assay. As 397 expected, p33 efficiently binds and shifts the (+)RNA carrying the p33RE (Fig. 8A, lanes 6 and 398 8) (35). However, addition of increasing amounts of recombinant CypA inhibited the formation 399 of p33:RNA complex in vitro (Fig. 8, lanes 2-3) . Interestingly, H 126 Q mutant also efficiently 400 inhibited the formation of p33:RNA complex in vitro (Fig. 8A, lanes 11-12) (Fig. 8B) . We found the purified recombinant 406
CypA and H 126 Q mutant strongly inhibited the recruitment of (+)repRNA by p33 and p92 407 replication proteins to the cellular membranes (Fig. 8B, lanes 5-6 and 7-8 versus 3-4) . These data 408 strongly support that CypA can inhibit (+)repRNA recruitment, which is critical for TBSV 409 replication (35, 39, 65, 66) . Moreover, the PPIase activity is not needed for this inhibitory 410
function. 411 412
CypA inhibits de novo initiation by the tombusvirus replicase in vitro. By binding to 413 the viral RNA and to the replication proteins, CypA might also interfere with RNA synthesis. To 414 test this, we performed an in vitro assay with affinity-purified tombusvirus replicase on added (-415 )-strand template in the presence or absence of recombinant CypA (Fig. 9A) . The detergent-416 solubilized and affinity-purified tombusvirus replicase from yeast lacks endogenous RNA, which 417 is removed during purification, and can only synthesize complementary RNA products on added 418 TBSV templates (22, 39, 67) . The purified replicase, unlike the membrane-bound replicase in the 419 CFE-based assay, cannot perform a complete cycle of RNA synthesis (22, 39, 67) . The purified 420 tombusvirus replicase produces three types of products on the exogenous DI-72 RNA: a full-421 length de novo initiated product (FL), internal initiation products (not shown) and 3' terminal 422 extension product (3'TEX) (Fig. 9B, lane 1) . Interestingly, the addition of CypA strongly 423 inhibited the FL product (up to 5x reduction, Fig. 9B, lanes 3 and 6) . The H 126 Q mutant was also 424 a strong inhibitor (Fig. 9B, lanes 4-5) , suggesting that CypA inhibits de novo initiation, which is 425 required for standard TBSV replication in infected cells. (Fig. 10A, lanes 1-4) . The inhibitory effect of CypA over-432 expression was even more pronounced in cpr1Δ/ts-ess1 yeast, resulting in 25% TBSV replication 433 only (Fig. 10B, lanes 1-4) . Similar to Cpr1p (29), the over-expression of CypA did not affect the 434 level of p33 replication protein in the two yeast strains tested, indicating that CypA is unlikely to 435 destabilize the replication proteins. These data established that, similar to Cpr1p (29), CypA is a 436 potent inhibitor of TBSV replication in yeast. 437
Interestingly, H 126 Q mutant was as potent an inhibitor of TBSV replication as the wt 438
CypA, when over-expressed in both yeast strains (Fig. 10A-B, lanes 9-12) . Thus, the PPIase 439 activity of CypA is not required for its inhibitory effect on TBSV replication. This finding is in 440 agreement with the CFE-based data. (Fig. 11A, lanes 13-20 versus 9-12) . 446
Over-expression of Roc1 (Fig. 11B) or Roc2 (not shown) did not have phenotypic effects on the 447 N. benthamiana plants. The plants over-expressing Roc1 were protected from the lethal necrosis 448 caused by tombusvirus infection (Fig. 11B) . Similarly, expression of CypA or H 126 Q mutant also 449 led to close to 10-fold reduction in tombusviral RNA (Fig. 11A) Since the E. coli expressed Cpr1p lacked inhibitory activity in the CFE-based TBSV 475 replication assay (52), we decided to dissect the mechanism by using the orthologous 476 mammalian CypA and the Arabidopsis Roc1 and Roc2 cyclophilins. Detailed mechanistic 477 studies revealed that CypA inhibits TBSV replication by inhibiting the viral (+)RNA recruitment 478 for replication and by blocking the VRC assembly. CypA also inhibits the RNA synthesis steps if 479 it gets recruited to the VRC during assembly. However, CypA does not seem to be able to enter 480 the already assembled VRC, suggesting that CypA cannot remodel the VRC once the membrane-481 bound VRC is formed. Altogether, these events lead to reduced RNA synthesis and potent 482 inhibition of TBSV replication. could be more exposed at the early stage before VRC assembly, than during the latter stages 500 when the membrane-bound VRCs are tightly protected (38, 43) . 501
Based on the in vitro, yeast and plant data with wt and PPIase mutant CypA, we suggest 502 that the RNA binding function of CypA could also be critical for its viral restriction function. 503 This is supported by the following observations: (i) The de novo initiated FL product decreased 504 in the presence of CypA (Fig. 9B); (ii) The H 126 Q mutant behaved similarly to the wt CypA in 505 inhibiting tombusvirus replication in vitro, in yeast and plant, although the H 126 Q mutant binds to 506 the viral replication proteins much less efficiently then the wt CypA; (iii) Also, both wt CypA 507 and H 126 Q mutant inhibit the selective binding of p33 replication protein to the p33RE (Fig. 8) . 508
These observations could be explained by the ability of CypA to bind viral RNA that hinders the 509 interaction of the viral RNA with the viral replication proteins. However, the possibility also 510 remains that the affinity of CypA(H 126 Q) to TBSV replication proteins ( Although most of the mechanistic studies were performed with the mammalian CypA 522 protein due to its high activity in vitro, we also obtained evidence that the Arabidopsis CypA-like 523
Roc1 and Roc2 cyclophilins also have similar inhibitory function in the CFE assay (Fig. 1) . In 524 addition, Roc1 and Roc2 also bind to both the viral replication proteins and the viral RNA ( 
